相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Chris Karlovich et al.
CLINICAL CANCER RESEARCH (2016)
Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI
Akito Hata et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
Kenneth S. Thress et al.
LUNG CANCER (2015)
Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
L. V. Sequist et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Next Generation of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
Conor E. Steuer et al.
CANCER (2015)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)
Christos Chouaid et al.
LUNG CANCER (2014)
Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
J. L. Kuiper et al.
LUNG CANCER (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Rebiopsy of Non-Small Cell Lung Cancer Patients With Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor
Akito Hata et al.
CANCER (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer
Jong-Mu Sun et al.
LUNG CANCER (2013)
An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting
K. Goto et al.
ANNALS OF ONCOLOGY (2012)
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer
Kang-Yi Su et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Repeat Biopsy for Mutational Analysis of Non-Small Cell Lung Cancers Resistant to Previous Chemotherapy: Adequacy and Complications
Hyun Jung Yoon et al.
RADIOLOGY (2012)
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
Maria E. Arcila et al.
CLINICAL CANCER RESEARCH (2011)
Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
Seiji Yano et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
David Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
